- Obniżka

Zamawiaj do paczkomatu
Płać wygodnie
Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej
Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów
Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates todays available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Opis
1. The HER2 alteration in breast cancer
2. HER2 testing in the era of changing guidelines
Advanced Disease
3. Optimal first-line treatment of HER2+ advanced disease
4. Second line therapy and beyond
5. HER2+ CNS metastases
Therapeutics
6. Neoadjuvant therapy
7. Adjuvant therapy
8. Outcomes based on HR status in early stage disease
9. De-escalation of therapy for small tumor
Toxicity considerations
10. Cardiac toxicity of HER2-targeted regimens
11. Non-cardiac toxicity of HER2-targeted therapy
Therapies on the horizon
12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)
13. Harnessing the immune system in HER2+ disease
14. Biosimilars